SLC7A3

Summary

SLC7A3 (solute carrier family 7 member 3, HGNC:11061) is a protein-coding gene on chromosome Xq13.1, encoding Cationic amino acid transporter 3 (Q8WY07). Uniporter that mediates the uptake of cationic L-amino acids such as L-arginine, L-lysine and L-ornithine.

This gene encodes a member of the solute carrier family 7. The encoded protein is a sodium-independent cationic amino acid transporter. Alternate splicing results in multiple transcripts that encoded the same protein.

Source: NCBI Gene 84889 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism spectrum disorder (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 65 total
• Druggable target: yes
• MANE Select transcript: NM_032803

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11061
Approved symbol	SLC7A3
Name	solute carrier family 7 member 3
Location	Xq13.1
Locus type	gene with protein product
Status	Approved
Aliases	CAT-3, ATRC3, FLJ14541
Ensembl gene	ENSG00000165349
Ensembl biotype	protein_coding
OMIM	300443
Entrez	84889

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 15 protein_coding

ENST00000298085, ENST00000374299, ENST00000921007, ENST00000921008, ENST00000921009, ENST00000921010, ENST00000921011, ENST00000921012, ENST00000921013, ENST00000921014, ENST00000921015, ENST00000921016, ENST00000921017, ENST00000921018, ENST00000921019

RefSeq mRNA: 2 — MANE Select: NM_032803 NM_001048164, NM_032803

CCDS: CCDS14404

Canonical transcript exons

ENST00000374299 — 12 exons

Exon	Start	End
ENSE00001092379	70927484	70927623
ENSE00001092380	70928145	70928257
ENSE00001092383	70926527	70926693
ENSE00001092384	70926070	70926178
ENSE00001092385	70926875	70927041
ENSE00001092386	70927282	70927384
ENSE00001092387	70927798	70928020
ENSE00001092388	70928844	70929002
ENSE00001092389	70928456	70928633
ENSE00001463110	70929628	70930022
ENSE00001877213	70930977	70931096
ENSE00001956189	70925579	70925943

Expression profiles

Bgee: expression breadth ubiquitous, 111 present calls, max score 92.69.

FANTOM5 (CAGE): breadth broad, TPM avg 6.6467 / max 389.2480, expressed in 270 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199535	6.6467	270

Top tissues by expression

228 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cauda epididymis	UBERON:0004360	92.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.82	gold quality
tibialis anterior	UBERON:0001385	82.19	silver quality
ventricular zone	UBERON:0003053	81.38	gold quality
thymus	UBERON:0002370	79.44	gold quality
ganglionic eminence	UBERON:0004023	77.61	gold quality
kidney epithelium	UBERON:0004819	76.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.84	gold quality
pancreatic ductal cell	CL:0002079	74.25	silver quality
mucosa of stomach	UBERON:0001199	72.54	gold quality
ileal mucosa	UBERON:0000331	71.85	gold quality
upper arm skin	UBERON:0004263	70.60	gold quality
body of uterus	UBERON:0009853	69.75	gold quality
cerebellar vermis	UBERON:0004720	68.54	gold quality
deltoid	UBERON:0001476	67.75	silver quality
nasal cavity epithelium	UBERON:0005384	67.59	gold quality
hypothalamus	UBERON:0001898	64.38	gold quality
sperm	CL:0000019	64.16	silver quality
smooth muscle tissue	UBERON:0001135	63.54	gold quality
corpus epididymis	UBERON:0004359	63.30	silver quality
parotid gland	UBERON:0001831	63.00	gold quality
caput epididymis	UBERON:0004358	62.99	silver quality
myometrium	UBERON:0001296	62.41	gold quality
decidua	UBERON:0002450	62.18	gold quality
quadriceps femoris	UBERON:0001377	61.72	gold quality
seminal vesicle	UBERON:0000998	60.86	silver quality
lateral nuclear group of thalamus	UBERON:0002736	60.42	gold quality
vena cava	UBERON:0004087	60.32	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	59.97	gold quality
epithelium of mammary gland	UBERON:0003244	59.65	silver quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	1259.67
E-ANND-3	yes	2.61

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting SLC7A3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-889-3P	99.40	69.76	2103
HSA-MIR-4742-3P	98.73	69.82	1803
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-3144-5P	97.64	65.45	646
HSA-MIR-125B-1-3P	91.57	67.67	56

Literature-anchored findings (GeneRIF, showing 5)

• is concluded that hCAT-3 is a passive transport system that conducts monovalent cations including L-Arg. (PMID:15737334)
• It is concluded that similar to hCAT-1, hCAT-3 activity is decreased by PKC via reduction of transporter molecules in the plasma membrane. (PMID:16332251)
• CAT1, CAT2, and CAT3 localized in adult brains but with uneven distribution. (PMID:22870827)
• knockdown impaired AMPK-PPAR-alpha signaling and resulted in lipid accumulation under glucose starvation in liver cells (PMID:25130427)
• rare hypomorphic variants of SLC7A3 exist in male individuals, SLC7A3 variants possibly contribute to the etiology of autism spectrum disorders in male subjects in association with other genetic factors (PMID:26215737)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc7a3a	ENSDARG00000020645
danio_rerio	slc7a3b	ENSDARG00000061566
mus_musculus	Slc7a3	ENSMUSG00000031297
rattus_norvegicus	Slc7a3	ENSRNOG00000004133
drosophila_melanogaster	mnd	FBGN0002778
drosophila_melanogaster	CG7255	FBGN0036493
drosophila_melanogaster	CG5535	FBGN0036764
drosophila_melanogaster	slif	FBGN0037203
drosophila_melanogaster	CG1607	FBGN0039844
caenorhabditis_elegans		WBGENE00000002
caenorhabditis_elegans		WBGENE00000003
caenorhabditis_elegans		WBGENE00000005
caenorhabditis_elegans	aat-9	WBGENE00000010
caenorhabditis_elegans		WBGENE00015197
caenorhabditis_elegans		WBGENE00017747

Paralogs (12): SLC7A2 (ENSG00000003989), SLC7A14 (ENSG00000013293), SLC7A9 (ENSG00000021488), SLC7A8 (ENSG00000092068), SLC7A4 (ENSG00000099960), SLC7A6 (ENSG00000103064), SLC7A5 (ENSG00000103257), SLC7A10 (ENSG00000130876), SLC7A1 (ENSG00000139514), SLC7A11 (ENSG00000151012), SLC7A7 (ENSG00000155465), SLC7A13 (ENSG00000164893)

Protein

Protein identifiers

Cationic amino acid transporter 3 — Q8WY07 (reviewed: Q8WY07)

Alternative names: Cationic amino acid transporter y+, Solute carrier family 7 member 3

All UniProt accessions (1): Q8WY07

UniProt curated annotations — full annotation on UniProt →

Function. Uniporter that mediates the uptake of cationic L-amino acids such as L-arginine, L-lysine and L-ornithine. The transport is sodium ions- and pH-independent, moderately trans-stimulated and is mediated by passive diffusion.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in thymus, uterus and testis. Detected at lower levels in brain, mammary gland, prostate, salivary gland and fetal spleen. In brain, highest expression in thalamus, hippocampus and amygdala.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the amino acid-polyamine-organocation (APC) superfamily. Cationic amino acid transporter (CAT) (TC 2.A.3.3) family.

RefSeq proteins (2): NP_001041629, NP_116192* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002293	AA/rel_permease1	Family
IPR004755	Cat_AA_permease	Family
IPR029485	CAT_C	Domain

Pfam: PF13520, PF13906

Catalyzed reactions (Rhea), 3 shown:

• L-arginine(in) = L-arginine(out) (RHEA:32143)
• L-lysine(in) = L-lysine(out) (RHEA:70935)
• L-ornithine(in) = L-ornithine(out) (RHEA:71199)

UniProt features (37 total): topological domain 15, transmembrane region 14, modified residue 2, sequence variant 2, sequence conflict 2, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WY07-F1	83.55	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 606, 618

Glycosylation sites (1): 232

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-352230	Amino acid transport across the plasma membrane

MSigDB gene sets: 96 (showing top): GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_AMINO_ACID_TRANSMEMBRANE_TRANSPORT, AATGGAG_MIR136, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_AMINO_ACID_TRANSPORT, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP, GOBP_BASIC_AMINO_ACID_TRANSPORT, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_ORGANIC_CATION_TRANSPORT, DOUGLAS_BMI1_TARGETS_UP, GOBP_IMPORT_INTO_CELL, LEE_AGING_CEREBELLUM_UP, ATF_01, GOBP_TRANSMEMBRANE_TRANSPORT, DR3_Q4

GO Biological Process (10): amino acid transport (GO:0006865), L-arginine import across plasma membrane (GO:0097638), L-lysine import across plasma membrane (GO:0097639), L-ornithine import across plasma membrane (GO:0097640), transport across blood-brain barrier (GO:0150104), ornithine transport (GO:0015822), transmembrane transport (GO:0055085), amino acid import across plasma membrane (GO:0089718), L-lysine transmembrane transport (GO:1903401), L-arginine transmembrane transport (GO:1903826)

GO Molecular Function (7): L-ornithine transmembrane transporter activity (GO:0000064), amino acid transmembrane transporter activity (GO:0015171), L-lysine transmembrane transporter activity (GO:0015189), L-arginine transmembrane transporter activity (GO:0061459), protein binding (GO:0005515), basic amino acid transmembrane transporter activity (GO:0015174), transmembrane transporter activity (GO:0022857)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
SLC-mediated transport of amino acids	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
amino acid import across plasma membrane	3
L-amino acid transmembrane transporter activity	3
transport	2
L-arginine transmembrane transport	2
L-lysine transmembrane transport	2
L-ornithine transmembrane transport	2
amino acid transmembrane transport	2
L-alpha-amino acid transmembrane transport	2
basic amino acid transmembrane transport	2
basic amino acid transmembrane transporter activity	2
vascular transport	1
amino acid transport	1
carboxylic acid transport	1
nitrogen compound transport	1
cellular process	1
import across plasma membrane	1
L-lysine transport	1
transmembrane transporter activity	1
binding	1
amino acid transmembrane transporter activity	1
transporter activity	1
transmembrane transport	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1072 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC7A3	COQ7	Q99807	697
SLC7A3	SLC7A13	Q8TCU3	531
SLC7A3	SLC16A2	P36021	474
SLC7A3	SLC7A6	Q92536	457
SLC7A3	CHIC1	Q5VXU3	433
SLC7A3	SLC7A4	O43246	428
SLC7A3	SLC1A4	P43007	409
SLC7A3	SLC25A35	Q3KQZ1	407
SLC7A3	SLC38A8	A6NNN8	399
SLC7A3	CDX4	O14627	396
SLC7A3	SVOPL	Q8N434	386
SLC7A3	SLC16A10	Q8TF71	380
SLC7A3	SLC3A2	P08195	378
SLC7A3	SLC3A1	Q07837	375
SLC7A3	SLC43A2	Q8N370	355

IntAct

71 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RXYLT1	FKTN	psi-mi:“MI:0914”(association)	0.710
SDC2	PDPK1	psi-mi:“MI:0914”(association)	0.640
SLC7A3	TMEM237	psi-mi:“MI:0915”(physical association)	0.560
SLC10A1	SLC7A3	psi-mi:“MI:0915”(physical association)	0.560
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
IPPK	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC2A5	RBFOX3	psi-mi:“MI:0914”(association)	0.530
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
B4GAT1	ADCY6	psi-mi:“MI:0914”(association)	0.530
RTN1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CLEC2D	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TXNDC15	ORC4	psi-mi:“MI:0914”(association)	0.350
RXYLT1	RTL8C	psi-mi:“MI:0914”(association)	0.350
WDFY2	U2SURP	psi-mi:“MI:0914”(association)	0.350
SLC18A1	LIMK2	psi-mi:“MI:0914”(association)	0.350
SDC2	METTL8	psi-mi:“MI:0914”(association)	0.350
SLC17A2	PSMD11	psi-mi:“MI:0914”(association)	0.350
LPAR6	DEGS1	psi-mi:“MI:0914”(association)	0.350
B4GAT1	ADCY6	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
DNAJC2	RPS3A	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
RAMP2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CMTM5	TMEM120B	psi-mi:“MI:0914”(association)	0.350

BioGRID (163): SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS), SLC7A3 (Affinity Capture-MS)

ESM2 similar proteins: A0JNI9, A8I499, B0UYF2, B3TP03, B5D5N9, O08812, O54701, O64759, O80668, P18581, P30823, P30825, P31637, P52569, P53793, P53794, P70423, Q08469, Q09143, Q09573, Q28677, Q28E01, Q5PR34, Q5R9C2, Q5RK27, Q63632, Q63633, Q6A4L1, Q6DCE8, Q80UP8, Q84MA5, Q8BG16, Q8BXR1, Q8GYB4, Q8TBB6, Q8W4K3, Q8WY07, Q91V14, Q924N4, Q9ASS7

Diamond homologs: A0JNI9, A8I499, B0UYF2, B3TP03, B5D5N9, O07576, O08812, O43246, O64759, P18581, P30823, P30825, P52569, P70423, Q09143, Q5PR34, Q6DCE8, Q797A7, Q84MA5, Q8BLQ7, Q8BXR1, Q8GYB4, Q8TBB6, Q8W4K3, Q8WY07, Q9C5D6, Q9LZ20, Q9SHH0, Q9SQZ0, Q8MH63, Q9ASS7, Q9GIP4, A0A1D8PPG4, A0A1D8PPI5, A2RHI9, P43059, P37103, A1L3M3, D3ZMM8, O34739

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	11
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1647 predictions. Top by Δscore:

Variant	Effect	Δscore
X:70926965:T:TA	donor_gain	1.0000
X:70926988:T:TA	donor_gain	1.0000
X:70927478:TGTTA:T	donor_loss	1.0000
X:70927479:GTTAC:G	donor_loss	1.0000
X:70927480:TTAC:T	donor_loss	1.0000
X:70927481:TACCT:T	donor_loss	1.0000
X:70927482:ACC:A	donor_loss	1.0000
X:70927483:C:CG	donor_loss	1.0000
X:70927483:CCTG:C	donor_gain	1.0000
X:70927619:GGAGG:G	acceptor_gain	1.0000
X:70927620:GAGG:G	acceptor_gain	1.0000
X:70927621:AGG:A	acceptor_gain	1.0000
X:70927622:GGC:G	acceptor_loss	1.0000
X:70927623:GCTGG:G	acceptor_loss	1.0000
X:70927624:C:CA	acceptor_loss	1.0000
X:70927624:C:CC	acceptor_gain	1.0000
X:70927625:T:C	acceptor_loss	1.0000
X:70927947:C:CT	acceptor_gain	1.0000
X:70927950:C:CT	acceptor_gain	1.0000
X:70927951:A:T	acceptor_gain	1.0000
X:70928838:CCTCA:C	donor_loss	1.0000
X:70928839:CTCAC:C	donor_loss	1.0000
X:70928840:TCACC:T	donor_loss	1.0000
X:70928841:CA:C	donor_loss	1.0000
X:70928842:ACCAG:A	donor_loss	1.0000
X:70928843:C:CG	donor_loss	1.0000
X:70930971:GCTTA:G	donor_loss	1.0000
X:70930973:TTAC:T	donor_loss	1.0000
X:70930974:TAC:T	donor_loss	1.0000
X:70930975:ACCA:A	donor_loss	1.0000

AlphaMissense

3961 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:70928164:G:C	F267L	0.999
X:70928164:G:T	F267L	0.999
X:70928166:A:G	F267L	0.999
X:70929665:G:C	F111L	0.999
X:70929665:G:T	F111L	0.999
X:70929667:A:G	F111L	0.999
X:70929655:A:G	W115R	0.998
X:70929655:A:T	W115R	0.998
X:70928153:G:T	A271D	0.997
X:70929648:A:G	L117P	0.997
X:70929681:C:A	G106V	0.997
X:70926146:G:C	S551R	0.996
X:70926146:G:T	S551R	0.996
X:70926148:T:G	S551R	0.996
X:70927282:C:A	R429M	0.996
X:70928162:T:A	D268V	0.996
X:70928173:A:C	F264L	0.996
X:70928173:A:T	F264L	0.996
X:70928175:A:G	F264L	0.996
X:70928992:A:C	S127R	0.996
X:70928992:A:T	S127R	0.996
X:70928994:T:G	S127R	0.996
X:70929657:C:T	G114D	0.996
X:70929682:C:G	G106R	0.996
X:70929695:G:C	S101R	0.996
X:70929695:G:T	S101R	0.996
X:70929697:T:G	S101R	0.996
X:70929756:C:T	G81E	0.996
X:70927956:G:C	C295W	0.995
X:70929681:C:T	G106D	0.995

dbSNP variants (sampled 300 via entrez): RS1000501955 (X:70928382 C>T), RS1001329802 (X:70927033 G>A,T), RS1001888615 (X:70930852 G>A), RS1002384696 (X:70928784 C>G,T), RS1003344841 (X:70931038 T>G), RS1003496038 (X:70927707 C>T), RS1003780631 (X:70931101 T>G), RS1004840524 (X:70927168 T>A,G), RS1005311409 (X:70931504 T>C,G), RS1005334667 (X:70931958 C>T), RS1005404759 (X:70932585 T>A), RS1005550092 (X:70928891 G>A,T), RS1005832934 (X:70929253 G>A), RS1007488880 (X:70929723 G>A), RS1007753472 (X:70926361 A>G)

Disease associations

OMIM: gene MIM:300443 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autism spectrum disorder	Limited	Autosomal dominant

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_93	Refractive error	3.000000e-16

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5209633 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC7 family

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	decreases expression, affects cotreatment	3
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
bisphenol A	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
dorsomorphin	increases expression, decreases expression, affects cotreatment	1
LDN 193189	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Vorinostat	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Arbutin	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Carbamazepine	affects expression	1
Diethylhexyl Phthalate	decreases expression, increases expression	1
Methotrexate	decreases expression	1
Thimerosal	decreases expression	1
Triclosan	decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Permethrin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5209617	Functional	Substrate uptake by the Cationic Amino Acid Transporter (CAT-3, SLC7A3) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC7A3 cells (PubChem AID: 1745863)	Membrane potential based transport assay for SLC7A3 using HEK293 JumpIn SLC7A3 OE cells

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TP12	HAP1 SLC7A3 (-) 1	Cancer cell line	Male
CVCL_TP13	HAP1 SLC7A3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder